Upon completion of the deal, Abcam would operate as a standalone company and brand within Danaher's Life Sciences segment, which makes and markets instruments and consumables for studying DNA and RNA, nucleic acid, proteins, metabolites and cells, with applications in the discovery, testing, and manufacture of new drugs, vaccines, and gene editing technologies. Last year, Danaher carved out of Life Sciences a Biotechnology segment that includes its bioprocessing and discovery and medical businesses and offers tools, consumables and services primarily used by customers to advance and accelerate R&D, manufacture and delivery of biologics. TMO: No "normalization" of orders Thermo Fisher shares sank 5.5% on Wednesday, from $458.26 to $433.18, after the tools giant reported its own quarterly revenue decline, citing factors similar to those that have served to lower Danaher's results.